منابع مشابه
Levetiracetam in L-dopa-induced dyskinesia.
Dyskinesia To the Editor: Levetiracetam is a novel antiepi-leptic drug used in the treatment of the partial crisis as an add-on to other antiepileptic drugs. Although the underlying mechanism of action of levetirace-tam is unknown, the metabolism of GABA appears to be involved. In particular , it may counteract neuronal hyper-synchronization of the firing patterns of neurons in the substantia n...
متن کاملNitric oxide, a new player in L-DOPA-induced dyskinesia?
L-3,4-Dihydroxyphenylalanine (L-DOPA) remains the most effective symptomatic treatment of Parkinson's disease (PD). However, the long-term use of L-DOPA causes, in combination with disease progression, the development of motor complications termed L-DOPA-induced dyskinesia (LID). LID is the result of profound modifications in the functional organization of the basal ganglia circuitry. There is ...
متن کاملPost- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
L-3,4-dihydroxyphenylalanine (L-DOPA) remains the most efficacious drug for the treatment of Parkinson's disease (PD), but causes adverse effects that limit its utility. L-DOPA-induced dyskinesia (abnormal involuntary movements) is a significant clinical problem that attracts growing scientific interest. Current notions attribute the development of dyskinesia to two main factors, viz. the loss ...
متن کاملmTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats.
The development of dyskinesia upon chronic L-DOPA treatment is a major complication for the management of the motor symptoms in Parkinson's disease (PD) patients. Efforts are made to understand the underlying mechanisms and identify targets for the pharmacological alleviation of dyskinesia without affecting the therapeutic effect of L-DOPA. Previous studies have shown that the mTOR pathway is h...
متن کاملThe pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
L-3,4-Dihydroxyphenylalanine (L-DOPA) remains the most effective symptomatic treatment of Parkinson's disease (PD). However, long-term administration of L-DOPA is marred by the emergence of abnormal involuntary movements, i.e., L-DOPA-induced dyskinesia (LID). Years of intensive research have yielded significant progress in the quest to elucidate the mechanisms leading to the development and ex...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Translational Neurodegeneration
سال: 2017
ISSN: 2047-9158
DOI: 10.1186/s40035-017-0071-y